Yingnan Fan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yingnan Fan has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
- Andrea On Yan Luk
Department of Medicine and Therapeutics, Faculty of Medicine The Chinese University of Hong Kong Hong Kong SAR China
6 shared publications - Alice Pik Shan Kong
Department of Medicine and Therapeutics, Faculty of Medicine The Chinese University of Hong Kong Hong Kong SAR China
4 shared publications - Elaine Chow
Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China
4 shared publications - Baoqi Fan
Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, Special Administrative Region, China
3 shared publications - Eric Siu Him Lau
Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong SAR, China
3 shared publications Hongjiang Wu
Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong Special Administrative Region
3 shared publications
Latest Publications
- 12 May 2026
- Published by American Diabetes Association in Diabetes Care
- Vol. 49 (7) , 1202-1212
Precision Medicine to Redefine Insulin Secretion and Monogenic Diabetes (PRISM): A Randomized Controlled Trial in Chinese Patients With Young-Onset Diabetes
OBJECTIVE: Young-onset type 2 diabetes (YOD) results from complex causes, calling for precision management. RESEARCH DESIGN AND METHODS: The Precision Medicine to Redefine Insulin Secretion and Monogenic Diabetes (PRISM) study was a single-center, two-arm, 3-year randomized controlled trial in which Chinese individuals aged 18 to 50 years with non–type 1 diabetes diagnosed at age ≤40 years were randomly assigned to intervention (Joint Asia Diabetes Evaluation [JADE]–PRISM) or usual clinic-based care (JADE only). The intervention included technologically guided assessment and use of biogenetic markers (autoantibodies, C-peptide, and common and rare genetic variants) to classify diabetes for 1-year intensified, algorithm-based treatment followed by two annual reviews by an endocrinologist-led multidisciplinary team. The primary end point was a composite of incident or progression of all diabetes-related complications. Secondary end points included attainment of three or more treatment targets (HbA1c <6.2%, blood pressure <120/75 mmHg, LDL cholesterol <1.2 mmol/L, triglycerides <1.2 mmol/L, and waist circumference <80 [women] or <85 cm [men]), proxies of β-cell function, and patient-reported outcome measures (PROMs). RESULTS: During 2020 to 2021, 884 participants (mean [SD] age 40.7 [6.5] years; mean [SD] age at diagnosis 32.5 [6.8] years; autoantibody positivity [n = 46]; monogenic diabetes [n = 23]; C-peptide <200 pmol/L [n = 82]; central obesity [n = 699]; dyslipidemia [n = 669]; hypertension [n = 588]; albuminuria [n = 313]; insulin treated [n = 250]) were randomly assigned to the JADE-PRISM (n = 441) or JADE-only group (n = 443). During the 3-year study, the primary end point developed in 116 participants (26.3%) in the JADE-PRISM group versus 125 (28.2%) in the JADE-only group (odds ratio 0.908 [95% CI 0.675–1.221]). In the JADE-PRISM group, 104 participants (23.8%) versus 54 in the JADE-only group (12.2%; P < 0.001) reached three or more treatment targets, with improved proxies of β-cell function and reduced emotional distress. CONCLUSIONS: A 3-year technology-enhanced, multicomponent program improved cardiometabolic status, proxies of β-cell function, and PROMs in individuals with YOD but did not reduce complications.
- 12 May 2026
- Published by American Diabetes Association in Diabetes Care
- Vol. 49 (7) , 1202-1212
Precision Medicine to Redefine Insulin Secretion and Monogenic Diabetes (PRISM): A Randomized Controlled Trial in Chinese Patients With Young-Onset Diabetes
OBJECTIVE: Young-onset type 2 diabetes (YOD) results from complex causes, calling for precision management. RESEARCH DESIGN AND METHODS: The Precision Medicine to Redefine Insulin Secretion and Monogenic Diabetes (PRISM) study was a single-center, two-arm, 3-year randomized controlled trial in which Chinese individuals aged 18 to 50 years with non–type 1 diabetes diagnosed at age ≤40 years were randomly assigned to intervention (Joint Asia Diabetes Evaluation [JADE]–PRISM) or usual clinic-based care (JADE only). The intervention included technologically guided assessment and use of biogenetic markers (autoantibodies, C-peptide, and common and rare genetic variants) to classify diabetes for 1-year intensified, algorithm-based treatment followed by two annual reviews by an endocrinologist-led multidisciplinary team. The primary end point was a composite of incident or progression of all diabetes-related complications. Secondary end points included attainment of three or more treatment targets (HbA1c <6.2%, blood pressure <120/75 mmHg, LDL cholesterol <1.2 mmol/L, triglycerides <1.2 mmol/L, and waist circumference <80 [women] or <85 cm [men]), proxies of β-cell function, and patient-reported outcome measures (PROMs). RESULTS: During 2020 to 2021, 884 participants (mean [SD] age 40.7 [6.5] years; mean [SD] age at diagnosis 32.5 [6.8] years; autoantibody positivity [n = 46]; monogenic diabetes [n = 23]; C-peptide <200 pmol/L [n = 82]; central obesity [n = 699]; dyslipidemia [n = 669]; hypertension [n = 588]; albuminuria [n = 313]; insulin treated [n = 250]) were randomly assigned to the JADE-PRISM (n = 441) or JADE-only group (n = 443). During the 3-year study, the primary end point developed in 116 participants (26.3%) in the JADE-PRISM group versus 125 (28.2%) in the JADE-only group (odds ratio 0.908 [95% CI 0.675–1.221]). In the JADE-PRISM group, 104 participants (23.8%) versus 54 in the JADE-only group (12.2%; P < 0.001) reached three or more treatment targets, with improved proxies of β-cell function and reduced emotional distress. CONCLUSIONS: A 3-year technology-enhanced, multicomponent program improved cardiometabolic status, proxies of β-cell function, and PROMs in individuals with YOD but did not reduce complications.
- 19 November 2025
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 231, 113000
Disparities of adiposity explained ethnic differences in insulin sensitivity and secretion traits in adolescents with normoglycaemia
- 19 November 2025
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 231, 113000
Disparities of adiposity explained ethnic differences in insulin sensitivity and secretion traits in adolescents with normoglycaemia
- Open Access
- 18 September 2025
- Published by Wiley in Diabetes/Metabolism Research and Reviews
- Vol. 41 (6) , e70087
Development of a Chinese‐Specific Clinical Model to Predict Maturity‐Onset Diabetes of the Young
Aims: Accurate identification of individuals with maturity‐onset diabetes of the young (MODY) can support precision diabetes management. However, diagnosing MODY is challenging due to overlapping clinical features with type 2 diabetes. We aimed to develop a prediction model for identifying Chinese with high likelihood of MODY for further genetic testing.Methods: We developed a logistic regression model using clinical data from an unselected cohort of 1021 Chinese with young‐onset (age at diagnosis ≤ 40) non‐type 1 diabetes enrolled in the Hong Kong Diabetes Register, 1.9% (n = 19) of whom had MODY (GCK‐, HNF1A‐, HNF4A‐ and HNF1B‐MODY) by molecular confirmation. We validated the model in an independent local cohort of 822 Chinese with young‐onset non‐type 1 diabetes. We compared the performance of the new Chinese‐specific MODY prediction model with an existing MODY probability calculator in the validation cohort.Results: The prediction model comprised the following clinical variables: current age, age at diagnosis, sex, body mass index, systolic blood pressure, HDL‐cholesterol, LDL‐cholesterol, triglyceride and fasting C‐peptide. It demonstrated acceptable discrimination of patients with MODY in the validation dataset, with an area under the curve of 0.813 (95% confidence interval 0.647–0.979). At the probability cut‐off of 50%, the model achieved a sensitivity of 72.7% and a specificity of 92.4%. It allows identification of one MODY case in every nine genetic tests conducted.Conclusion: We developed a comprehensive Chinese‐specific MODY prediction model. This model can be used in unselected Chinese with young‐onset non‐type 1 diabetes to identify high‐risk individuals for genetic testing.
- 18 September 2025
- Published by Wiley in Diabetes/Metabolism Research and Reviews
- Vol. 41 (6) , e70087
Open AccessDevelopment of a Chinese‐Specific Clinical Model to Predict Maturity‐Onset Diabetes of the Young
Aims: Accurate identification of individuals with maturity‐onset diabetes of the young (MODY) can support precision diabetes management. However, diagnosing MODY is challenging due to overlapping clinical features with type 2 diabetes. We aimed to develop a prediction model for identifying Chinese with high likelihood of MODY for further genetic testing.Methods: We developed a logistic regression model using clinical data from an unselected cohort of 1021 Chinese with young‐onset (age at diagnosis ≤ 40) non‐type 1 diabetes enrolled in the Hong Kong Diabetes Register, 1.9% (n = 19) of whom had MODY (GCK‐, HNF1A‐, HNF4A‐ and HNF1B‐MODY) by molecular confirmation. We validated the model in an independent local cohort of 822 Chinese with young‐onset non‐type 1 diabetes. We compared the performance of the new Chinese‐specific MODY prediction model with an existing MODY probability calculator in the validation cohort.Results: The prediction model comprised the following clinical variables: current age, age at diagnosis, sex, body mass index, systolic blood pressure, HDL‐cholesterol, LDL‐cholesterol, triglyceride and fasting C‐peptide. It demonstrated acceptable discrimination of patients with MODY in the validation dataset, with an area under the curve of 0.813 (95% confidence interval 0.647–0.979). At the probability cut‐off of 50%, the model achieved a sensitivity of 72.7% and a specificity of 92.4%. It allows identification of one MODY case in every nine genetic tests conducted.Conclusion: We developed a comprehensive Chinese‐specific MODY prediction model. This model can be used in unselected Chinese with young‐onset non‐type 1 diabetes to identify high‐risk individuals for genetic testing.
- 14 October 2023
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 205, 110954
Comparison of beta-cell function between Hong Kong Chinese with young-onset type 2 diabetes and late-onset type 2 diabetes
- 14 October 2023
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 205, 110954
Comparison of beta-cell function between Hong Kong Chinese with young-onset type 2 diabetes and late-onset type 2 diabetes
- 20 May 2023
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 202, 110728
Higher incidence of cardiovascular-kidney complications in Chinese with youth-onset type 2 diabetes versus youth-onset type 1 diabetes attenuated by control of cardio-metabolic risk factors: A population-based prospective cohort study in Hong Kong
- 20 May 2023
- Published by Elsevier in Diabetes Research and Clinical Practice
- Vol. 202, 110728
Higher incidence of cardiovascular-kidney complications in Chinese with youth-onset type 2 diabetes versus youth-onset type 1 diabetes attenuated by control of cardio-metabolic risk factors: A population-based prospective cohort study in Hong Kong
- Open Access
- 16 March 2023
- Published by Elsevier in The Lancet Regional Health - Western Pacific
- Vol. 34, 100730
Incident cardiovascular-kidney disease, diabetic ketoacidosis, hypoglycaemia and mortality in adult-onset type 1 diabetes: a population-based retrospective cohort study in Hong Kong
- 16 March 2023
- Published by Elsevier in The Lancet Regional Health - Western Pacific
- Vol. 34, 100730
Open AccessIncident cardiovascular-kidney disease, diabetic ketoacidosis, hypoglycaemia and mortality in adult-onset type 1 diabetes: a population-based retrospective cohort study in Hong Kong